PuromycinPuromycin - High-quality laboratory reagent available from Gentaur. Catalog: 804-HY-B1743-01.804-HY-B1743-01804-HY-B1743-01Business & Industrial > Science & LaboratoryPuromycin
Gentaur
EUR12027-02-22

Puromycin

CAT:
804-HY-B1743-01
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Puromycin - image 1

Puromycin

  • Description:

    Puromycin dihydrochloride is the dihydrochloride salt of puromycin. Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis.
  • Product Name Alternative:

    CL13900
  • UNSPSC:

    12352005
  • Hazard Statement:

    H302
  • Target:

    Antibiotic; Bacterial; Parasite
  • Type:

    Natural Products
  • Related Pathways:

    Anti-infection
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Infection
  • Assay Protocol:

    https://www.medchemexpress.com/Puromycin.html
  • Purity:

    99.55
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic) |H2O : 1 mg/mL (ultrasonic)
  • Smiles:

    OC[C@@H]1[C@@H](NC([C@@H](N)CC2=CC=C(OC)C=C2)=O)[C@H]([C@H](N3C=NC4=C3N=CN=C4N(C)C)O1)O
  • Molecular Formula:

    C22H29N7O5
  • Molecular Weight:

    471.51
  • Precautions:

    H302
  • References & Citations:

    [1]Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92.|[2]Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28 (5) :1176-82.|[3]Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6 (4) :275-7.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -20°C, 3 years (Powder)
  • Scientific Category:

    Natural Products
  • Clinical Information:

    Launched
  • Isoform:

    Aminoglycoside
  • Citation 01:

    Acta Diabetol. 2025 Jul 2.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Acta Pharmacol Sin. 2025 May;46 (5) :1236-1249.|Adv Funct Mater. 2019, 1808556.|Adv Healthc Mater. 2025 Apr;14 (10) :e2404501.|Adv Sci (Weinh) . 2024 Dec 25:e2406822.|Adv Sci (Weinh) . 2025 Apr;12 (15) :e2413882.|Adv Sci (Weinh) . 2025 Jun 5:e06529.|Adv Tradit Med. 2025 Aug 8.|Biochem Pharmacol. 2017 Mar 15:128:12-25.|Biochem Pharmacol. 2026 Jan;243 (Pt 2) :117529.|Biochim Biophys Acta Mol Basis Dis. 2025 Oct;1871 (7) :167965.|Biol Direct. 2024 Nov 26;19 (1) :122.|bioRxiv. 2023 Jun 17.|bioRxiv. 2024 Sep 29:2024.09.26.615290.|bioRxiv. 2025 March 24.|bioRxiv. 2025 Nov 6.|BMC Biol. 2025 Feb 28;23 (1) :66.|Br J Cancer. 2025 Jul 28.|Cancer Cell Int. 2019 Jul 24:19:192.|Cancer Cell Int. 2025 Jun 9;25 (1) :207.|Cancer Commun (Lond) . 2025 Jun 20.|Cancer Immunol Res. 2023 Jul 5;11 (7) :875-894.|Cell Death Dis. 2025 Apr 11;16 (1) :274.|Cell Death Dis. 2025 Oct 6;16 (1) :696.|Cell Signal. 2019 Jun:58:119-130.|Commun Biol. 2025 Jul 29;8 (1) :1127.|Commun Biol. 2025 Nov 20;8 (1) :1626.|Development. 2024 Nov 1;151 (21) :dev202899.|Evid Based Complement Alternat Med. 2019 Mar 24:2019:1635837.|Genes Dis. 2025 Apr 1.|Hepatology. 2021 Apr;73 (4) :1327-1345.|Hum Cell. 2025 Oct 4;38 (6) :170.|Indian J Pharm Educ. 2024 Jun 21.|Int Immunopharmacol. 2025 Mar 26:150:114266.|Int J Biol Macromol. 2025 Jan 24:140310.|Int J Biol Macromol. 2025 Sep;321 (Pt 1) :145938.|Int J Biol Sci. 2024 Oct 14;20 (14) :5548-5575.|Int J Biol Sci. 2025 Jun 20;21 (9) :4215-4230.|Int J Oncol. 2020 Jul;57 (1) :161-170.|Int J Oral Sci. 2025 Feb 28;17 (1) :15.|J Cell Biol. 2025 Dec 1;224 (12) :e202412005.|J Cell Mol Med. 2019 Feb;23 (2) :954-966.|J Control Release. 2025 Jul 10:383:113814.|J Ethnopharmacol. 2025 Aug 18;353 (Pt B) :120435.|J Exp Clin Cancer Res. 2016 Nov 7;35 (1) :173. |J Exp Clin Cancer Res. 2025 Aug 19;44 (1) :245.|J Exp Clin Cancer Res. 2025 Mar 4;44 (1) :81.|J Extracell Vesicles. 2025 Aug;14 (8) :e70146.|J Extracell Vesicles. 2025 Sep;14 (9) :e70162.|J Hepatocell Carcinoma. 2024 Sep 18:11:1763-1775.|J Mol Histol. 2025 Sep 13;56 (5) :312.|J Pathol. 2025 Jul 21.|J Transl Med. 2024 Nov 22;22 (1) :1052.|Liver Res. 2025 Sep 22.|Microbiome. 2025 Jan 27;13 (1) :27.|Mol Biomed. 2025 Nov 27;6 (1) :122.|Mol Carcinog. 2025 Jan;64 (1) :57-71.|Mol Neurobiol. 2025 Jul;62 (7) :9290-9305.|Mol Neurobiol. 2025 Nov 14;63 (1) :41.|Nat Aging. 2025 Sep 10.|Nat Commun. 2024 Nov 6;15 (1) :9578.|Nat Commun. 2025 Jan 2;16 (1) :263.|Nat Commun. 2025 Jun 2;16 (1) :5101.|Nat Commun. 2025 Oct 10;16 (1) :9027.|Nat Metab. 2025 May;7 (5) :985-1003.|Nat Protoc. 2025 Oct 8.|NPJ Precis Oncol. 2025 May 3;9 (1) :127.|Onco Targets Ther. 2019 Jan 25:12:835-848.|Oncogene. 2024 Nov;43 (47) :3469-3482.|Oncogene. 2025 Oct 11.|Oncol Lett. 2025 Jan 15;29 (3) :143.|Oncol Rep. 2026 Jan;55 (1) :5.|Orphanet J Rare Dis. 2025 Aug 1;20 (1) :392.|Pharm Res. 2025 Aug;42 (8) :1315-1329.|Placenta. 2024 Dec:158:156-164.|PLoS One. 2017 Oct 10;12 (10) :e0185565.|Proc Natl Acad Sci U S A. 2025 Feb 25;122 (8) :e2424906122.|Purdue University. 2025.|R Soc Open Sci. 2018 Aug 29;5 (8) :172376.|Redox Biol. 2025 Aug 5:86:103806.|Reprod Biol Endocrinol. 2025 Sep 24;23 (1) :121.|Res Sq. 2024 Nov 07.|Research Square Print. 2025 May 28.|Respir Res. 2025 Apr 28;26 (1) :168.|Sci Adv. 2025 Feb 28;11 (9) :eadq2881.|Sci Immunol. 2025 Jun 27;10 (108) :eadn1630.|SSRN. 2025 Jan 24.|SSRN. 2025 Oct 9.|SSRN. 2025 Sep 16.|Theranostics. 2020 May 16;10 (14) :6483-6499. |Theranostics. 2021 Mar 5;11 (10) :5045-5060.|Toxicol Appl Pharmacol. 2019 Sep 1:378:114625.|Transl Res. 2023 Sep:259:62-71.|Vet Sci. 2025 Jan 13;12 (1) :52.|Virology. 2025 May:606:110504.|Viruses. 2024 Dec 18;16 (12) :1932.|World J Clin Oncol. 2025 Jun 24;16 (6) :106197.|World J Diabetes. 2025 Mar 15;16 (3) :101328.|World J Surg Oncol. 2025 Nov 14;23 (1) :434.|ACS Omega. 2025 Apr 7;10 (15) :15461-15470.|Acta Pharmacol Sin. 2023 Jul;44 (7) :1464-1474.|Adv Mater. 2023 Jan;35 (1) :e2206793.|Adv Sci (Weinh) . 2024 Apr;11 (16) :e2308531.|Adv Sci (Weinh) . 2024 Dec 25:e2407064.|Adv Sci (Weinh) . 2024 Dec;11 (46) :e2407967.|Adv Sci (Weinh) . 2024 Jun 26:e2404822.|Adv Sci (Weinh) . 2025 Apr;12 (13) :e2404961.|Adv Sci (Weinh) . 2025 Aug 22:e06225.|Adv Sci (Weinh) . 2025 Jul 23:e17248.|Adv Sci (Weinh) . 2025 Oct 27:e12966.|Aging (Albany NY) . 2021 Jun 8;13 (11) :14892-14909.|Aging. 2020 Sep 14;12 (17) :17122-17136.|Am J Cancer Res. 2023 May 15;13 (5) :1718-1743.|Am J Cancer Res. 2023 Sep 15;13 (9) :4222-4234.|Am J Transl Res. 2021 Apr 15;13 (4) :2331-2349.|Am J Transl Res. 2021 May 15;13 (5) :4360-4375.|Amino Acids. 2025 Aug 22;57 (1) :42.|Anal Biochem. 2021 Oct 15:631:114357.|Antioxid Redox Signal. 2023 Jan;38 (1-3) :115-136.|Antioxidants (Basel) . 2023 Aug 18;12 (8) :1634.|Arch Biochem Biophys. 2023 Jul 15:743:109642.|Autophagy. 2021 Dec;17 (12) :4083-4101.|Autophagy. 2024 Jul 26:1-17.|Autophagy. 2025 Jun;21 (6) :1192-1211.|Bioact Mater. 2021 Nov 12:13:149-160.|Biochem Biophys Res Commun. 2021 Nov 26:580:48-55.|Biochem Biophys Res Commun. 2022 Jan 1:586:34-41.|Biochem Biophys Res Commun. 2022 Oct 15:625:23-30.|Biochem Pharmacol. 2020 Apr;174:113776.|Biochem Pharmacol. 2024 Jul 10:116418.|Biochem Pharmacol. 2024 Jul 10:116422.|Biochem Pharmacol. 2024 May 9:225:116256.|Biochem Pharmacol. 2025 Aug 9;242 (Pt 2) :117222.|Biochim Biophys Acta Mol Basis Dis. 2024 Apr 20;1870 (5) :167195.|Biochim Biophys Acta Mol Basis Dis. 2024 Aug 5:167453.|Biochim Biophys Acta Mol Basis Dis. 2025 Jan 3:167650.|Biochim Biophys Acta Mol Cell Res. 2024 Jun 3:119768.|Biodes Manuf. 03 March 2022.|Biodes Manuf. 2022 Apr 18.|Biol Res. 2024 May 17;57 (1) :30.|Biomed Pharmacother. 2020 Jan;121:109578.|bioRxiv. 2023 Mar 31:2023.03.29.534783.|bioRxiv. 2023 Oct 4.|bioRxiv. 2024 August 30.|bioRxiv. 2024 Mar 29.|bioRxiv. 2025 April 10.|bioRxiv. 2025 Aug 17.|bioRxiv. 2025 Jun 21:2025.06.20.660750.|bioRxiv. April 11, 2022.|BMC Cancer. 2018 Feb 13;18 (1) :182. |Bone Res. 2025 Mar 3;13 (1) :30.|Bull Cancer. 2023 Apr;110 (4) :342-351.|Burns Trauma. 2025 Sep 18.|Cancer Commun (Lond) . 2023 Jan;43 (1) :123-149.|Cancer Immunol Res. 2023 May 3;11 (5) :600-613.|Cancer Invest. 2021 May;39 (5) :423-434.|Cancer Lett. 2020 Nov 1;492:162-173.|Cancer Lett. 2021 Jul 28:511:36-46.|Cancer Lett. 2021 Oct 10:518:266-277.|Cancer Lett. 2024 Jun 1:591:216848.|Cancer Lett. 2024 Mar 31:585:216674.|Cancer Lett. 2025 Oct 2:218073.|Cancer Manag Res. 2021 Nov 30;13:8915-8928.|Cancer Med. 2019 Oct;8 (13) :5903-5915.|Cancer Res. 2023 Jul 5;83 (13) :2187-2207.|Cancer Sci. 2024 Aug;115 (8) :2565-2577.|Cell Biol Toxicol. 2024 Aug 7;40 (1) :65.|Cell Commun Signal. 2022 Jun 15;20 (1) :87.|Cell Commun Signal. 2025 Nov 13;23 (1) :496.|Cell Death Dis. 2020 Dec 2;11 (12) :1032.|Cell Death Dis. 2021 Oct 14;12 (10) :944.|Cell Death Dis. 2021 Sep 9;12 (9) :842.|Cell Death Dis. 2022 Apr 18;13 (4) :360.|Cell Death Dis. 2023 Feb 11;14 (2) :107.|Cell Death Dis. 2023 Nov 25;14 (11) :765.|Cell Death Dis. 2023 Oct 6;14 (10) :653.|Cell Death Dis. 2025 Jan 16;16 (1) :23.|Cell Death Dis. 2025 Jun 17;16 (1) :452.|Cell Death Dis. 2019 Nov 21;10 (12) :879. |Cell Death Discov. 2021 Aug 30;7 (1) :226.|Cell Death Discov. 2021 May 1;7 (1) :89.|Cell Death Discov. 2022 Apr 23;8 (1) :222.|Cell Death Discov. 2022 Dec 16;8 (1) :493.|Cell Death Discov. 2022 Feb 22;8 (1) :77.|Cell Death Discov. 2022 Oct 28;8 (1) :432.|Cell Discov. 2025 Mar 11;11 (1) :22.|Cell Metab. 2025 Sep 2;37 (9) :1907-1925.e14.|Cell Metab. 2025 Sep 24:S1550-4131 (25) 00385-7.|Cell Mol Biol (Noisy-le-grand) . 2024 Jun 5;70 (6) :122-128.|Cell Mol Immunol. 2024 Jun;21 (6) :546-560.|Cell Rep Med. 2025 Jan 16:101922.|Cell Rep. 2024 Aug 22;43 (9) :114662.|Cell Rep. 2024 Dec 13;43 (12) :115060.|Cell Rep. 2024 Feb 27;43 (2) :113739.|Cell Rep. 2024 Mar 23;43 (4) :114003.|Cell Rep. 2025 Jan 18;44 (2) :115226.|Cell Signal. 2021 Mar:79:109878.|Cell Signal. 2025 Jan 3:111583.|Clin Cancer Res. 2025 Jul 8.|Clin Epigenetics. 2022 Dec 2;14 (1) :164.|Clin Transl Oncol. 2021 Sep;23 (9) :1942-1954.|Clin Transl Oncol. 2023 May;25 (5) :1425-1435.|Commun Biol. 2022 Aug 30;5 (1) :887.|Commun Biol. 2024 Dec 26;7 (1) :1701.|Commun Biol. 2025 Mar 26;8 (1) :496.|Comput Biol Med. 2024 Feb:169:107975.|Dig Liver Dis. 2023 Jul;55 (7) :967-981.|Dis Markers. 2022 Sep 23;2022:8402116.|DNA Cell Biol. 2022 Apr;41 (4) :447-455.|Drug Resist Updat. 2025 Apr 17:81:101246.|Electrophoresis. 2025 Sep 23.|EMBO Rep. 2021 Aug 4;22 (8) :e52205.|EMBO Rep. 2025 Sep 22.|Environ Health. 2025 Nov 28, XXXX (XXX) .|Environ Toxicol. 2023 Jun;38 (6) :1318-1331.|Environ Toxicol. 2024 Feb;39 (2) :803-814.|Exp Cell Res. 2023 Apr 11;427 (1) :113598.|Exp Cell Res. 2023 Jul 1;428 (1) :113613.|Exp Cell Res. 2024 Apr 16;438 (1) :114038.|Exp Mol Med. 2022 Jul;54 (7) :890-905.|Exp Mol Pathol. 2021 Dec:123:104704.|FASEB J. 2025 Jun 15;39 (11) :e70674.|Food Funct. 2024 Dec 9;15 (24) :11875-11887.|Front Biosci (Landmark Ed) . 2025 Apr 30;30 (5) :27094.|Front Oncol. 2021 Apr 21:11:669560.|Gene. 2024 Aug 22:931:148855.|Genes (Basel) . 2022 Sep 29;13 (10) :1760.|Heliyon. 2022 Dec 6;8 (12) :e12118.|Heliyon. 2023 Aug 9;9 (8) :e19034.|Heliyon. 2023 Nov 23;9 (12) :e22595.|Hum Cell. 2023 Sep;36 (5) :1755-1772.|Int Immunopharmacol. 2023 Sep:122:110616.|Int Immunopharmacol. 2024 Nov 16;143 (Pt 3) :113622.|Int Immunopharmacol. 2025 Aug 26:164:115417.|Int J Biol Macromol. 2023 Jun 30:241:124476.|Int J Biol Macromol. 2025 Dec;333 (Pt 2) :148750.|Int J Mol Sci. 2023 Sep 23;24 (19) :14476.|Int J Oncol. 2023 Apr;62 (4) :45.|Int J Oncol. 2024 Apr;64 (4) :45.|J Appl Toxicol. 2023 Oct;43 (10) :1421-1435.|J Biochem Mol Toxicol. 2025 Apr;39 (4) :e70210.|J Biol Chem. 2021 Jan-Jun:296:100276.|J Biol Chem. 2021 Jan-Jun:296:100413.|J Biol Chem. 2023 Mar;299 (3) :102961.|J Cancer. 2023 May 8;14 (8) :1309-1320.|J Cancer. 2024 Sep 9;15 (17) :5762-5772.|J Cell Mol Med. 2023 Apr;27 (8) :1045-1055.|J Ethnopharmacol. 2023 Aug 10:312:116446.|J Exp Clin Cancer Res. 2021 Nov 25;40 (1) :373.|J Exp Clin Cancer Res. 2022 Mar 28;41 (1) :111.|J Exp Clin Cancer Res. 2023 Nov 6;42 (1) :294.|J Exp Clin Cancer Res. 2023 Oct 3;42 (1) :258.|J Exp Clin Cancer Res. 2025 Mar 14;44 (1) :97.|J Exp Clin Cancer Res. 2025 Mar 19;44 (1) :99.|J Hematol Oncol. 2021 Jul 10;14 (1) :109.|J Nanobiotechnology. 2025 Nov 18;23 (1) :717.|J Transl Med. 2024 Jun 20;22 (1) :584.|J Transl Med. 2024 May 21;22 (1) :485.|J Virol. 2024 Jun 28:e0083024.|Life Sci. 2022 Mar 15:293:120320.|mBio. 2023 Dec 19;14 (6) :e0168823.|MedComm (2020) . 2024 May 31;5 (6) :e576.|Metabolism. 2025 Nov 4:175:156426.|Microbiol Res. 2025 May 14:298:128223.|Mol Cancer. 2024 May 6;23 (1) :90.|Mol Cancer. 2019 Aug 22;18 (1) :127. |Mol Carcinog. 2023 Sep;62 (9) :1338-1354.|Mol Carcinog. 2025 Jul 17.|Mol Cell Biochem. 2021 Jun;476 (6) :2503-2512.|Mol Cell. 2023 Dec 21;83 (24) :4494-4508.e6.|Mol Cell. 2023 Dec 7;83 (23) :4370-4385.e9.|Mol Cell. 2024 Aug 1:S1097-2765 (24) 00593-8.|Mol Pharm. 2024 Jul 1;21 (7) :3447-3458.|Mol Ther Nucleic Acids. 2025 May 14;36 (2) :102560.|Molecules. 2023 Jan 22;28 (3) :1103.|Nat Commun. 2019 Dec 2;10 (1) :5492. |Nat Commun. 2022 Mar 10;13 (1) :1248.|Nat Commun. 2025 Aug 7;16 (1) :7309.|Nat Commun. 2025 Feb 27;16 (1) :2039.|Nat Commun. 2025 Mar 14;16 (1) :2511.|Nat Commun. 2025 Sep 11;16 (1) :8263.|Neural Regen Res. 2025 Apr 29.|Neuro Oncol. 2022 Dec 1;24 (12) :2107-2120.|NPJ Precis Oncol. 2024 Mar 1;8 (1) :58.|Nucleic Acids Res. 2024 Apr 12;52 (6) :3291-3309.|Oncogene. 2022 Feb;41 (6) :770-781.|Oncogene. 2023 Sep;42 (39) :2878-2891.|Oncol Lett. 2023 Dec 18;27 (2) :59.|Oncol Rep. 2021 Feb;45 (2) :523-534.|Oncol Rep. 2023 Aug;50 (2) :148.|Oncotargets Ther. 2020 Sep 30;13:9701-9719.|PeerJ. 2022 Jun 6:10:e13535.|Phytomedicine. 2023 Jun:114:154769.|Poult Sci. 2023 Oct;102 (10) :102864.|Reprod Biomed Online. 2023 Nov;47 (5) :103253.|Research (Wash D C) . 2022 Aug 3:2022:9832128.|Research (Wash D C) . 2025 Mar 18:8:0635.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 Nov 25.|Research Square Preprint. 2023 Sep 27.|Research Square Print. 2022 Aug.|Research Square Print. 2023 Mar 15.|Sci Adv. 2025 Jun 27;11 (26) :eadq9643.|Sci Bull. 2025 Nov 25:S2095-9273 (25) 01198-3.|Sci China Life Sci. 2025 Jan;68 (1) :204-218.|Sci Rep. 2022 Nov 5;12 (1) :18809.|Sci Rep. 2025 Apr 30;15 (1) :15207.|Science. 2024 Feb 2;383 (6682) :eadh4859.|Signal Transduct Target Ther. 2022 Feb 28;7 (1) :54.|Signal Transduct Target Ther. 2024 Dec 18;9 (1) :352.|SSRN. 2021 Jun.|STAR Protoc. 2022 Apr 13;3 (2) :101296.|STAR Protoc. 2022 Nov 2;3 (4) :101808.|Stem Cell Res Ther. 2024 Dec 2;15 (1) :458.|Stem Cell Rev Rep. 2023 May;19 (4) :1019-1033.|Stem Cells Int. 2020 Aug 29:2020:8860185.|Thorac Cancer. 2024 May 8.|Transl Oncol. 2024 Jul 3:47:101950.|Transl Oncol. 2024 Jul:45:101958.|University of Bonn. 2025 Feb.|Vet Microbiol. 2023 Sep:284:109823.|Virology. 2025 Jan 7:603:110397.|Virus Res. 2023 Apr 15:328:199086.
  • CAS Number:

    [53-79-2]